Skip to main content

Aldeyra Therapeutics, Inc. (ALDX)

NASDAQ: ALDX · IEX Real-Time Price · USD
8.50
-0.07 (-0.82%)
After-hours:Sep 17, 2021 4:55 PM EDT
8.57
0.04 (0.47%)
At close: Sep 17, 4:00 PM
Market Cap495.89M
Revenue (ttm)n/a
Net Income (ttm)-46.39M
Shares Out57.86M
EPS (ttm)-1.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,710,840
Open8.55
Previous Close8.53
Day's Range8.18 - 8.59
52-Week Range6.21 - 15.95
Beta1.70
AnalystsStrong Buy
Price Target25.67 (+199.5%)
Est. Earnings DateNov 4, 2021

About ALDX

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The compan...

IndustryBiotechnology
IPO DateMay 2, 2014
Employees10
Stock ExchangeNASDAQ
Ticker SymbolALDX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ALDX stock is "Strong Buy." The 12-month stock price forecast is 25.67, which is an increase of 199.53% from the latest price.

Price Target
$25.67
(199.53% upside)
Analyst Consensus: Strong Buy

News

Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participat...

1 week ago - Business Wire

Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today ...

2 weeks ago - Business Wire

Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today ...

1 month ago - Business Wire

Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate

The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) ADX-2191 to treat retinitis pigmentosa (RP). ADX-2191 is a methotrexate for intravitreal injection.

1 month ago - Benzinga

Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Trea...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ADX-2191 (...

1 month ago - Business Wire

Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will participate in analyst-l...

1 month ago - Business Wire

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discus...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, August 5, 2021 to report financial results for the quarter en...

1 month ago - Business Wire

Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer

The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.

1 month ago - Zacks Investment Research

Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate

The FDA has granted Orphan Drug Designation to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) ADX-2191 (methotrexate for intravitreal injection) for primary vitreoretinal lymphoma (PVRL).  PVRL is a rare ocu...

1 month ago - Benzinga

Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Trea...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company...

1 month ago - Business Wire

Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today ...

2 months ago - Business Wire

Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate...

3 months ago - Business Wire

Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve...

4 months ago - Business Wire

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2021 Financial Results and Discuss...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, May 6, 2021 to report financial results for the quarter ended...

4 months ago - Business Wire

Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve...

4 months ago - Business Wire

Why Aldeyra Therapeutics Stock Is Sinking Today

The company plans to conduct a public stock offering.

4 months ago - The Motley Fool

Aldeyra Seeks To Raise $125M Via Equity To Support Reproxalap US Application

Aldeyra Therapeutics Inc (NASDAQ: ALDX) intends to sell $125 million shares of its common stock in an underwritten public offering.  Underwriters will have an option to purchase up to an additional $18....

4 months ago - Benzinga

Aldeyra Therapeutics, Inc. Announces Proposed $125 Million Public Offering of Common Stock

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve...

4 months ago - Business Wire

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

Cyclerion Therapeutics, Inc. (NASDAQ: CYCN), Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), DermTech, Inc. (NASDAQ: DMTK) and Bionano Genomics, Inc. (NASDAQ: BNGO) ...

Other symbols:BNGODMTKCYCNSLGL
4 months ago - Benzinga

Why Aldeyra Therapeutics Stock Is Soaring Today

The company reported great clinical results for its lead pipeline candidate.

4 months ago - The Motley Fool

Aldeyra Therapeutics Stock Is Trading Higher On Acing Allergic Conjunctivitis Study With Reproxalap

Aldeyra Therapeutics Inc (NASDAQ: ALDX) has announced positive top-line results from the Phase 3 INVIGORATE trial evaluating 0.25% reproxalap, in patients with allergic conjunctivitis. The 95-subject tr...

4 months ago - Benzinga

Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 IN...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve...

4 months ago - Business Wire

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE C...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve...

4 months ago - Business Wire

Aldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business Highlights

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve...

6 months ago - Business Wire

Aldeyra Therapeutics to Present at the OIS Dry Eye Innovation Showcase on March 11, 2021

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will discuss the potential of...

6 months ago - Business Wire